Last reviewed · How we verify
NCT06783270: CRISPR-TIL
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Recruiting now
Phase 1
Last updated 20 January 2025
What this trial tests
Phase 1 trial testing TIL therapy in Melanoma Metastatic in 10 participants. Currently enrolling.
Timeline
16 December 2024
Primary endpoint
1 January 2027
1 January 2027
1 January 2028
Quick facts
| Lead sponsor | Inge Marie Svane |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 16 December 2024 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2028 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- TIL therapy — full drug profile →
Conditions studied
- Melanoma Metastatic — all drugs for Melanoma Metastatic →
Sponsor
Inge Marie Svane — full company profile →
Who can join
Adults 18 to 75, any sex, with Melanoma Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess wether it is safe and feasible to treat patients with tumor infiltrating lymphocytes that have been silenced for PD-1, using CRISPR-Cas9.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges.
Chen R, Johnson J, Rezazadeh A, Dudek AZ. · · 2025 · cited 4× · PMID 40765841 · DOI 10.1136/bmjonc-2024-000566 -
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.
Coukos G, Donia M, Gastman BR, Goff SL, et al · · 2025 · cited 1× · PMID 41320228 · DOI 10.1136/jitc-2025-013420 -
CRISPR-Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics.
Rutkowska A, Strózik T, Wasiak T, Ciunowicz D, et al · · 2026 · PMID 41972732 · DOI 10.3390/cells15070644 -
Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a review.
Wu JF, Abid MA, Singh SP, Mohlere V, et al · · 2026 · PMID 41958653 · DOI 10.3389/fimmu.2026.1801722 -
HosTIL territory: mapping the landscape of toxicity in TIL therapy.
Woodford R, Demiguelarroyo MJ, Jethra R, Lorigan PC, et al · · 2026 · PMID 41956543 · DOI 10.1136/jitc-2025-014378 -
Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions.
Song Y, Mo Y, Chen S, Chen Y, et al · · 2026 · PMID 41768369 · DOI 10.1002/mco2.70635 -
Melanoma treatment in the era of nanotechnology and precision medicine.
da Cruz AF, Colella F, Grasso G, Onesto V, et al · · 2025 · PMID 41419864 · DOI 10.1186/s12951-025-03851-8 -
Ex Vivo Gene and Cell Therapy in Hematopoietic Stem Cells.
Petrova IO, Smirnikhina SA. · · 2025 · PMID 41373623 · DOI 10.3390/ijms262311466
Verify or expand the search:
- PubMed search for NCT06783270
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TIL therapy
Trials testing the same drug.
- NCT05417750 — A Phase I Study of GC101 TIL in Advanced Solid Tumors · Phase 1 · completed
Other recruiting trials for Melanoma Metastatic
Currently open trials in the same condition.
- NCT06889610 — A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. · Phase 2 · recruiting
- NCT06767306 — Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma · Phase 2 · recruiting
- NCT07050940 — Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma · NA · recruiting
- NCT06784648 — Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metast · Phase 1, PHASE2 · active not recruiting
- NCT07376317 — Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIM · Phase 2 · active not recruiting
Other Inge Marie Svane trials
Trials by the same sponsor.
- NCT07501117 — Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma · Phase 1 · not yet recruiting
- NCT06204991 — To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma · Phase 1 · recruiting
- NCT04904185 — ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma · Phase 1 · terminated
- NCT04611126 — T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer · Phase 1, PHASE2 · terminated
- NCT04810156 — Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06783270 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Inge Marie Svane
- Last refreshed: 20 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06783270.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing